1. Home
  2. SLS vs CCRD Comparison

SLS vs CCRD Comparison

Compare SLS & CCRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLS
  • CCRD
  • Stock Information
  • Founded
  • SLS 2012
  • CCRD 1973
  • Country
  • SLS United States
  • CCRD United States
  • Employees
  • SLS N/A
  • CCRD N/A
  • Industry
  • SLS Biotechnology: Pharmaceutical Preparations
  • CCRD
  • Sector
  • SLS Health Care
  • CCRD
  • Exchange
  • SLS Nasdaq
  • CCRD Nasdaq
  • Market Cap
  • SLS 169.6M
  • CCRD 157.9M
  • IPO Year
  • SLS N/A
  • CCRD N/A
  • Fundamental
  • Price
  • SLS $1.71
  • CCRD $26.40
  • Analyst Decision
  • SLS
  • CCRD Hold
  • Analyst Count
  • SLS 0
  • CCRD 1
  • Target Price
  • SLS N/A
  • CCRD $21.00
  • AVG Volume (30 Days)
  • SLS 2.9M
  • CCRD 29.2K
  • Earning Date
  • SLS 05-13-2025
  • CCRD 05-08-2025
  • Dividend Yield
  • SLS N/A
  • CCRD N/A
  • EPS Growth
  • SLS N/A
  • CCRD 187.14
  • EPS
  • SLS N/A
  • CCRD 0.86
  • Revenue
  • SLS N/A
  • CCRD $61,011,000.00
  • Revenue This Year
  • SLS N/A
  • CCRD $17.35
  • Revenue Next Year
  • SLS N/A
  • CCRD N/A
  • P/E Ratio
  • SLS N/A
  • CCRD $30.51
  • Revenue Growth
  • SLS N/A
  • CCRD 12.31
  • 52 Week Low
  • SLS $0.77
  • CCRD $11.57
  • 52 Week High
  • SLS $2.12
  • CCRD $28.00
  • Technical
  • Relative Strength Index (RSI)
  • SLS 54.26
  • CCRD 69.77
  • Support Level
  • SLS $1.36
  • CCRD $25.01
  • Resistance Level
  • SLS $2.12
  • CCRD $27.41
  • Average True Range (ATR)
  • SLS 0.18
  • CCRD 1.37
  • MACD
  • SLS -0.01
  • CCRD 0.19
  • Stochastic Oscillator
  • SLS 46.05
  • CCRD 75.08

About SLS SELLAS Life Sciences Group Inc.

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

About CCRD CoreCard Corporation

CoreCard Corp is engaged in the business of providing technology solutions and processing services to the financial technology and services market. It designs, develops and markets a comprehensive suite of software solutions to program managers, accounts receivable businesses, financial institutions, retailers and processors to manage their credit and debit cards, prepaid cards, private label cards, fleet cards, buy now pay later programs, loyalty programs and accounts receivable and loan transactions. The CoreCard software platform and modules include CoreENGINE, CoreISSUE, CoreFRAUD, CoreCOLLECT, CoreAPP, CoreMONEY and CoreACQUIRE. Its customers are located in the U.S, European Union and the Middle East of which key revenue is derived from the U.S.

Share on Social Networks: